Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
24 oct. 2021 15h30 HE
|
Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
18 oct. 2021 07h00 HE
|
Phathom Pharmaceuticals
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus...
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
07 oct. 2021 11h41 HE
|
PAVmed Inc.
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
20 sept. 2021 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
31 août 2021 07h45 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
10 août 2021 08h00 HE
|
Phathom Pharmaceuticals
Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling...
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
02 août 2021 08h30 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Endoluminal Suturing Devices Market revenue to cross USD 119.8 Mn by 2027: Global Market Insights Inc.
22 juil. 2021 07h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, July 22, 2021 (GLOBE NEWSWIRE) -- According to latest report “Endoluminal Suturing Devices Market by Application (Bariatric Surgery Gastrointestinal Defects, Gastroesophageal...
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
02 mars 2020 09h30 HE
|
PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...
PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
19 déc. 2019 09h30 HE
|
PAVmed Inc.
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer First patients to undergo testing...